Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

Arturo Vega-Ruiz, Jorge E. Cortes, Matjaz Sever, Taghi Manshouri, Alfonso Quintás-Cardama, Raja Luthra, Hagop M. Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

Gain-of-function D816V point mutation within the kinase domain of the transmembrane receptor KIT is found in the great majority of patients with systemic mastocytosis (SM) and is attractive therapeutic target. Twenty patients with SM were enrolled during 2003-2005 in phase II clinical trial with imatinib mesylate (400 mg daily), a KIT inhibitor. Median time on therapy was 9 months (range, 0.5-44+). Only one patient, with D816V KIT mutation-negative FIP1L1-PDGFRα-negative SM-HES, achieved complete remission (now lasting for 44 months). Six other patients reported symptomatic improvement, including two with D816V KIT mutation-positive SM (one reported improvement in diarrhea and the other in fatigue). Other patients had no benefit. Imatinib was relatively well tolerated. Our study confirms that imatinib therapy does not result in appreciable clinical activity in patients with D816V mutation-positive SM, but may result in a significant benefit in occasional patient with D816V mutation-negative SM.

Original languageEnglish (US)
Pages (from-to)1481-1484
Number of pages4
JournalLeukemia Research
Volume33
Issue number11
DOIs
StatePublished - Nov 1 2009
Externally publishedYes

Fingerprint

Systemic Mastocytosis
Mutation
Therapeutics
Phase II Clinical Trials
Imatinib Mesylate
Point Mutation
Fatigue
Diarrhea
Phosphotransferases

Keywords

  • Imatinib mesylate
  • KIT D816V mutation
  • Systemic mastocytosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Vega-Ruiz, A., Cortes, J. E., Sever, M., Manshouri, T., Quintás-Cardama, A., Luthra, R., ... Verstovsek, S. (2009). Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leukemia Research, 33(11), 1481-1484. https://doi.org/10.1016/j.leukres.2008.12.020

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. / Vega-Ruiz, Arturo; Cortes, Jorge E.; Sever, Matjaz; Manshouri, Taghi; Quintás-Cardama, Alfonso; Luthra, Raja; Kantarjian, Hagop M.; Verstovsek, Srdan.

In: Leukemia Research, Vol. 33, No. 11, 01.11.2009, p. 1481-1484.

Research output: Contribution to journalArticle

Vega-Ruiz, A, Cortes, JE, Sever, M, Manshouri, T, Quintás-Cardama, A, Luthra, R, Kantarjian, HM & Verstovsek, S 2009, 'Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis', Leukemia Research, vol. 33, no. 11, pp. 1481-1484. https://doi.org/10.1016/j.leukres.2008.12.020
Vega-Ruiz, Arturo ; Cortes, Jorge E. ; Sever, Matjaz ; Manshouri, Taghi ; Quintás-Cardama, Alfonso ; Luthra, Raja ; Kantarjian, Hagop M. ; Verstovsek, Srdan. / Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. In: Leukemia Research. 2009 ; Vol. 33, No. 11. pp. 1481-1484.
@article{56eaee3ffd8a4bdf8fea6173028d2e8c,
title = "Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis",
abstract = "Gain-of-function D816V point mutation within the kinase domain of the transmembrane receptor KIT is found in the great majority of patients with systemic mastocytosis (SM) and is attractive therapeutic target. Twenty patients with SM were enrolled during 2003-2005 in phase II clinical trial with imatinib mesylate (400 mg daily), a KIT inhibitor. Median time on therapy was 9 months (range, 0.5-44+). Only one patient, with D816V KIT mutation-negative FIP1L1-PDGFRα-negative SM-HES, achieved complete remission (now lasting for 44 months). Six other patients reported symptomatic improvement, including two with D816V KIT mutation-positive SM (one reported improvement in diarrhea and the other in fatigue). Other patients had no benefit. Imatinib was relatively well tolerated. Our study confirms that imatinib therapy does not result in appreciable clinical activity in patients with D816V mutation-positive SM, but may result in a significant benefit in occasional patient with D816V mutation-negative SM.",
keywords = "Imatinib mesylate, KIT D816V mutation, Systemic mastocytosis",
author = "Arturo Vega-Ruiz and Cortes, {Jorge E.} and Matjaz Sever and Taghi Manshouri and Alfonso Quint{\'a}s-Cardama and Raja Luthra and Kantarjian, {Hagop M.} and Srdan Verstovsek",
year = "2009",
month = "11",
day = "1",
doi = "10.1016/j.leukres.2008.12.020",
language = "English (US)",
volume = "33",
pages = "1481--1484",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

AU - Vega-Ruiz, Arturo

AU - Cortes, Jorge E.

AU - Sever, Matjaz

AU - Manshouri, Taghi

AU - Quintás-Cardama, Alfonso

AU - Luthra, Raja

AU - Kantarjian, Hagop M.

AU - Verstovsek, Srdan

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Gain-of-function D816V point mutation within the kinase domain of the transmembrane receptor KIT is found in the great majority of patients with systemic mastocytosis (SM) and is attractive therapeutic target. Twenty patients with SM were enrolled during 2003-2005 in phase II clinical trial with imatinib mesylate (400 mg daily), a KIT inhibitor. Median time on therapy was 9 months (range, 0.5-44+). Only one patient, with D816V KIT mutation-negative FIP1L1-PDGFRα-negative SM-HES, achieved complete remission (now lasting for 44 months). Six other patients reported symptomatic improvement, including two with D816V KIT mutation-positive SM (one reported improvement in diarrhea and the other in fatigue). Other patients had no benefit. Imatinib was relatively well tolerated. Our study confirms that imatinib therapy does not result in appreciable clinical activity in patients with D816V mutation-positive SM, but may result in a significant benefit in occasional patient with D816V mutation-negative SM.

AB - Gain-of-function D816V point mutation within the kinase domain of the transmembrane receptor KIT is found in the great majority of patients with systemic mastocytosis (SM) and is attractive therapeutic target. Twenty patients with SM were enrolled during 2003-2005 in phase II clinical trial with imatinib mesylate (400 mg daily), a KIT inhibitor. Median time on therapy was 9 months (range, 0.5-44+). Only one patient, with D816V KIT mutation-negative FIP1L1-PDGFRα-negative SM-HES, achieved complete remission (now lasting for 44 months). Six other patients reported symptomatic improvement, including two with D816V KIT mutation-positive SM (one reported improvement in diarrhea and the other in fatigue). Other patients had no benefit. Imatinib was relatively well tolerated. Our study confirms that imatinib therapy does not result in appreciable clinical activity in patients with D816V mutation-positive SM, but may result in a significant benefit in occasional patient with D816V mutation-negative SM.

KW - Imatinib mesylate

KW - KIT D816V mutation

KW - Systemic mastocytosis

UR - http://www.scopus.com/inward/record.url?scp=68649118339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68649118339&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2008.12.020

DO - 10.1016/j.leukres.2008.12.020

M3 - Article

C2 - 19193436

AN - SCOPUS:68649118339

VL - 33

SP - 1481

EP - 1484

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 11

ER -